BGI extends cash tender offer to purchase all outstanding shares of Complete Genomics

Published on February 2, 2013 at 1:03 AM · No Comments

BGI-Shenzhen ("BGI") announced today that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics, Inc. (NASDAQ: GNOM) ("Complete") to 12:00 midnight (New York City time) on Wednesday, February 6, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, February 1, 2013. 

Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on February 1, 2013, approximately 30,836,847 shares, or approximately 87%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.

BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers LLP. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins LLP.

SOURCE BGI-Shenzhen

Posted in: Business / Finance

Tags:

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
(optional)
Post